WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US Improves access for patients living with osteoporosis and ...

The Business Research Company's X-linked Hypophosphatemia Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034 The Business Research Company's Latest Report Explores ...

Shift of phosphorus from extracellular to intracellular compartments, decreased gastrointestinal absorption, and increased urinary losses, are the primary mechanisms of hypophosphatemia ...